I am a neuroscientist using robust statistical methods to identify effective neuroprotectants for stroke. I am examining the use of neuroprotection and novel imaging approaches to extend the utility of thrombolysis, and testing the hypothesis that neuropr
Gene Profiling To Develop A Neuroprotective Strategy In A Large Animals Model Of Following Ischaemic Stroke.
Funder
National Health and Medical Research Council
Funding Amount
$359,897.00
Summary
Stroke affects 15 million people worldwide each year. At present, the diagnosis and treatment of stroke is not optimal. The use of gene profiling may provide us with information that could allow us to more accurately identify individuals at risk of stroke, predict stroke outcome and effectively treat stroke patients. In addition, by using a targeted approach to therapy we have the potential to reduce brain swelling and improve outcome following stroke with neuroprotective agents.
Characterisation Of Substance P Antagonists As A Novel Therapeutic Intervention For Use In Traumatic Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$241,650.00
Summary
Traumatic brain injury (TBI) is responsible for more deaths in Australians under 45 years of age than any other cause. The economic and social cost of head injury to the community is enormous with billions of dollars spent each year on the management and rehabilitation of trauma patients. Despite the enormity of this public health problem, no effective treatment currently exists. A number of studies have demonstrated that much of the morbidity following TBI is associated with the development of ....Traumatic brain injury (TBI) is responsible for more deaths in Australians under 45 years of age than any other cause. The economic and social cost of head injury to the community is enormous with billions of dollars spent each year on the management and rehabilitation of trauma patients. Despite the enormity of this public health problem, no effective treatment currently exists. A number of studies have demonstrated that much of the morbidity following TBI is associated with the development of a secondary injury process that occurs between hours to days after the insult. This delayed progression of injury suggests that appropriate pharmacologic intervention can prevent, or at least attenuate, this secondary injury process with a resultant improvement in outcome. Over the past 15 years, a number of groups, including ours, have been investigating the secondary mechanisms associated with the development of functional deficits after TBI. Our previous studies have demonstrated that decline in brain free magnesium is associated with functional deficits after experimental brain injury, and that magnesium administration after injury can improve outcome. Magnesium is now on clinical trial as a pharmacologic intervention. Recent studies have suggested that magnesium decline facilitates neurogenic inflammation, which has been associated with oedema formation, oxidative damage and cell death. Although a number of neuropeptides have been implicated in this process, it is thought that substance P release is closely associated with these pathophysiological processes. Therefore, inhibiting neuropeptide release, or inhibiting substance P binding, may offer a novel therapeutic approach for the attenuation of oedema and development of neurologic deficits after TBI. This proposal will use a combined biochemical, pharmacologic and behavioural approach to characterise the role of neuropeptides in brain trauma, and attempt to develop a novel therapy for use in clinical trauma.Read moreRead less
Interactions Between Injured Neurons, Astrocytes And Metallothionein
Funder
National Health and Medical Research Council
Funding Amount
$478,067.00
Summary
We have found that the protein, metallothionein, which protects the brain after injury or during neurodegenerative disease acts in a more complex way than previously thought, including a direct action on injured neurons as well as on the originating cell, astrocytes. Elucidating each component of metallothionein action will help us understand how cells interact in the brain after injury, and excitingly, offers an opportunity to develop an enhanced therapeutic strategy based on this protein.
Organic Brain Damage After Non-fatal Opioid Overdose
Funder
National Health and Medical Research Council
Funding Amount
$244,858.00
Summary
The study will provide the first data on the level and nature of brain damage due to opioid overdose. The extent to which overdose survivors suffer brain damage has important implications for clinical management, particularly in relation to behavioural problems. It will also provide the first data on brain damage and drug treatment performance. Screening of those with an overdose history may lead to specialised management of these individuals with the potential for improved treatment outcome.
Understanding And Preventing Secondary Degeneration Following CNS Injury
Funder
National Health and Medical Research Council
Funding Amount
$409,147.00
Summary
After neurotrauma, tissue escaping initial injury undergoes secondary degeneration; tissue loss spreads, function worsens. In the complex brain and spinal cord it is difficult to distinguish vulnerable tissue. Using the visual system as a model I will precisely identify cells and processes of secondary degeneration, determine if vulnerable tissue can be rescued by drugs stopping toxic calcium influx and if rescued circuits work properly. The work has implications for neurotrauma and glaucoma.
Reinstating Emotion Perception After Brain Damage: An Experimental Approach
Funder
National Health and Medical Research Council
Funding Amount
$338,421.00
Summary
Many people with traumatic brain injury (TBI) cannot recognise emotions in others. This disrupts social behaviour leading to isolation and unemployment. In this project we determine whether: (1) selectively attending to a person's expression improves empathy and emotion recognition; (2) whether mimicking an expression improves recognition of the emotion and; (3) whether poor recognition of emotional tone of voice (prosody) and audiovisual displays is improved by focusing on voice or face alone.